Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer
NCT06379217Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 5
01
Overview
Phase 1, open-label trial of lutetium lu 177 vipivotide tetraxetan, lutetium Lu 177 dotatate and AAA503 in Prostatic Neuroendocrine Carcinoma (NEPC) (3 arms), sponsored by Novartis. Primary endpoints: Number/extent of lesions with at least a moderate uptake of any of the Radioligand Imaging (RLI) and Percentage changes in quantitative PET parameters. Started Jul 2024; status: active, not recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetanlutetium Lu 177 dotatateAAA503
03
Conditions
Prostatic Neuroendocrine Carcinoma (NEPC)
Beyond the preview
Go deeper on NCT06379217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06379217.